Clinical utility of emerging biomarkers in prostate cancer liquid biopsies
| Autor: | Gerald W. Verhaegh, Levi Groen, Emmy Boerrigter, Jack A. Schalken, Nielka P. van Erp |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
0301 basic medicine Oncology Treatment response medicine.medical_specialty Clinical Decision-Making Urinalysis Exosomes Pathology and Forensic Medicine 03 medical and health sciences Prostate cancer 0302 clinical medicine Circulating tumor cell Internal medicine Urological cancers Radboud Institute for Molecular Life Sciences [Radboudumc 15] Biomarkers Tumor Genetics Humans Medicine Biomarker discovery Liquid biopsy Molecular Biology business.industry Liquid Biopsy Disease Management Prostatic Neoplasms Cancer Neoplastic Cells Circulating Prognosis medicine.disease Prostate-specific antigen 030104 developmental biology Molecular Diagnostic Techniques 030220 oncology & carcinogenesis Urological cancers Radboud Institute for Health Sciences [Radboudumc 15] Molecular Medicine Biomarker (medicine) Disease Susceptibility business Cell-Free Nucleic Acids Blood Chemical Analysis |
| Zdroj: | Expert Review of Molecular Diagnostics, 20, 2, pp. 219-230 Expert Review of Molecular Diagnostics, 20, 219-230 |
| ISSN: | 1473-7159 |
| DOI: | 10.1080/14737159.2019.1675515 |
| Popis: | Contains fulltext : 218088.pdf (Publisher’s version ) (Open Access) Introduction: Prostate cancer (PCa) is one of the most common malignancies in men and a major cause of cancer deaths among men worldwide. Prostate specific antigen (PSA) monitoring and histopathological examination of tumor biopsies remain gold standards in PCa diagnostics. These clinical parameters are not well suited for patient stratification, predicting and monitoring treatment response. On the other hand, liquid biopsies offer a unique opportunity to easily isolate tumor-derived material for longitudinal clinical assessment.Areas covered: In this review we focus on the clinical application of novel liquid biomarkers that have the potential to monitor and stratify patients in order to achieve better therapeutic effects and improve clinical outcomes. Enumeration and characterization of circulating tumor cells (CTCs), tumor-educated platelets, exosomes, and cell-free nucleic acids have been studied for their clinical utility in PCa diagnostics, prognostics, monitoring treatment response and guiding treatment choice.Expert opinion: Liquid biomarkers have high potential to be used for prognosis, monitoring treatment response and guiding treatment selection. Although there is a remarkable progress in PCa biomarker discovery, their clinical validation is very limited. Research should be focused on biomarker validation and the incorporation of these biomarkers in clinical practice. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|